Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Epidemiological analysis of mammary tumors in female dogs in Japan: a study based on Kyushu-Okinawa region.
Vet J
January 2025
Laboratory of Veterinary Histopathology, Pathogenetic and Preventive Veterinary Science, Joint Faculty of Veterinary Medicine, National University Corporation Kagoshima University, 1-21-24 Korimoto, Kagoshima, 890-8580 JAPAN.
Canine mammary tumors (CMTs) are common tumors in female dogs (FDs), and at least nearly half of these lesions of malignant. We examined the epidemiology of CMTs in Japan using excisional biopsy cases (n = 7,802) collected from 2005 to 2023 in the Kyushu-Okinawa region. We investigated the prevalence, effects of breed, neutering, and age on CMT and malignant CMT (mCMT) risk through general statistics and multivariate analyses.
View Article and Find Full Text PDFReactivation of latent HIV-1 by the glucocorticoid receptor modulator AZD9567.
J Virol
January 2025
Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany.
One key determinant of HIV-1 latency reversal is the activation of the viral long terminal repeat (LTR) by cellular transcription factors such as NF-κB and AP-1. Interestingly, the activity of these two transcription factors can be modulated by glucocorticoid receptors (GRs). Furthermore, the HIV-1 genome contains multiple binding sites for GRs.
View Article and Find Full Text PDFBackground: LIGHT (oLaparib In HRD-Grouped Tumor types; NCT02983799) prospectively evaluated olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer (PSROC) assigned to cohorts by known BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: germline BRCAm (gBRCAm), somatic BRCAm (sBRCAm), HRD-positive non-BRCAm, and HRD-negative. At the primary analysis, olaparib treatment demonstrated activity across all cohorts, with greatest efficacy in terms of objective response rate and progression-free survival observed in the g/sBRCAm cohorts. The authors report final overall survival (OS).
View Article and Find Full Text PDFIdentification of SETD4 as an Onco-Immunological Biomarker Encompassing the Tumor Microenvironment, Prognoses, and Therapeutic Responses in Various Human Cancers.
Immun Inflamm Dis
January 2025
Second Department of Oncology, Guangdong Second Provincial General Hospital, Guangzhou, China.
Background: SET domain-containing protein 4 (SETD4) is a histone methyltransferase that has been shown to modulate cell proliferation, differentiation, and inflammatory responses by regulating histone H4 trimethylation (H4K20me3). Previous reports have demonstrated its function in the quiescence of cancer stem cells as well as drug resistance in several cancers. A limited number of systematic studies have examined SETD4's role in the tumor microenvironment, pathogenesis, prognosis, and therapeutic response.
View Article and Find Full Text PDFPrognostic Significance and Therapeutic Potential of SERPINE1 in Head and Neck Squamous Cell Carcinoma.
Cancer Med
January 2025
Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Background: This study aims to elucidate the expression pattern of SERPINE1, assess its prognostic significance, and explore potential therapeutic drugs targeting this molecule.
Methods And Results: In this study, we delved into the variations in gene mutation, methylation patterns, and expression levels of SERPINE1 in head and neck squamous cell carcinoma (HNSCC) and normal tissues, leveraging comprehensive analyses of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. The connection between the biological function of the gene and prognosis was scrutinized through immune infiltration and enrichment analyses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!